Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review
The DOI matches its Crossref record; 484 of the 491 references it cites were found in a registry or an index.
Abstract
Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus. Because many women with polycystic ovary syndrome (PCOS) are insulin resistant, metformin was introduced in clinical practice to treat these patients also. Moreover, metformin's effect has other targets beside its insulin-sensitizing action. The present review was aimed at describing all evidence-based and potential uses of metformin in PCOS patients. In particular, we will analyze the uses of metformin not only for the treatment of all PCOS-related disturbances such as menstrual disorders, anovulatory infertility, increased abortion, or complicated pregnancy risk, hyperandrogenism, endometrial, metabolic and cardiovascular abnormalities, but also for the prevention of the syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the beneficial effects of metformin are increasingly evident, especially when combined with lifestyle modifications, improving the pathogenetic mechanisms underlying PCOS, restoring ovarian function, and improving metabolic profile, especially insulin sensitivity and, unlike COCs, lipoprotein pattern [49].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [49]
In the citing paper
“Metformin has been used extensively in DM2, is the most studied in PCOS, and has the most reassuring safety profile. 222”
From Assessment and management of polycystic ovary syndrome: Summary of an evidence-based guideline (2011) · cites this paper as [222]
Citations
Cites
4 retracted
Activation of the AMP-activated Protein Kinase by the Anti-diabetic Drug Metformin in Vivo
Zou, M.-H., Kirkpatrick, S. S., Davis, B. J., Nelson, J. S., Wiles, W. G., Schlattner, U., Neumann, D., Brownlee, M., Freeman, M. B., & Goldman, M. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404421200 · Cited by 478
RetractedClomiphene citrate for ovulation induction in women with oligo-amenorrhoea
Hughes, E. G., Collins, J. A., & Vandekerckhove, P. (1996) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000056 · Cited by 78
RetractedWei, Z., Cao, Y., Cong, L., Zhou, P., Zhang, Z., & Li, J. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.07.1385 · Cited by 37
RetractedKoçak, İ., & Üstün, C. (2006) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2006.00401.x · Cited by 24
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866
Research works printed but not linked: 5
- 2005, American Association of Clinical Endocrinologists position statements on metabolic and cardiovascular consequences of polycystic ovary syndrome., Endocr Pract, 11, 126
- Deaton, 1991, Hyperandrogenism and uterine bleeding., Infertil Reprod Med Clin North Am, 2, 561
- 1992, Recent advances in medically assisted conception., WHO Tech Rep Ser, 820, 1
- Sonntag, 2005, Metformin alters insulin signaling and viability of human granulosa cells., Fertil Steril, 84, 1173, 10.1016/j.fertnstert.2005.04.043 · DOI
- Koschinsky, 1988, Influence of metformin on vascular cell proliferation., Diabetes Metab, 14, 566
Cited by
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Polycystic ovary syndrome: etiology, pathogenesis and diagnosis
Goodarzi, M. O., Dumesic, D. A., Chazenbalk, G., & Azziz, R. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.217 · Cited by 1,488
“As first-step therapy for anovulation, no consistent evidence suggests that metformin is better than clomiphene citrate regarding cumulative ovulation, pregnancy or live-birth rates”
BackgroundThe Mammalian Ovary from Genesis to Revelation
Edson, M. A., Nagaraja, A. K., & Matzuk, M. M. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0012 · Cited by 820
“For a more extensive review of the pathophysiology and potential genes involved in polycystic ovarian syndrome, the reader is referred to previous work in this journal (272, 273).”
Background
Metadata
- Authors
- Palomba, S., Falbo, A., Zullo, F., & Orio, F.
- Affiliations
- Magna Graecia University (IT)
- Parthenope University of Naples (IT)
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2008-12-04
- Volume
- 30
- Issue
- 1
- Pages
- 1-50
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2160472557
- Cited by
- 426
- References
- 491
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 20 · 2023: 28 · 2022: 25 · 2021: 18 · 2020: 15 · 2019: 19 · 2018: 19 · 2017: 15 · 2016: 18 · 2015: 26 · 2014: 37 · 2013: 40 · 2012: 33
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutial research information system (Parthenope University of Naples) (submittedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- metformin, polycystic ovary syndrome, insulin sensitization, insulin resistance, menstrual disorders, anovulatory infertility, pregnancy complications, hyperandrogenism, endometrial abnormalities, cardiovascular risk, PCOS prevention, type 2 diabetes
- MeSH terms
- Anovulation, Cardiovascular Diseases, Endometrium, Female, Humans, Hypoglycemic Agents, Menstruation Disturbances, Metformin, Obesity, Polycystic Ovary Syndrome, Pregnancy, Pregnancy Complications, Quality of Life, Endometrial Neoplasms, Hyperandrogenism, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review. https://app.cochat.ai/papers/10.1210/er.2008-0030
- The paper
- Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009). Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review. Endocrine Reviews. https://doi.org/10.1210/er.2008-0030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.